Pierantoni Luca, Andreozzi Laura, Ambretti Simone, Dondi Arianna, Biagi Carlotta, Baccelli Francesco, Lanari Marcello
Division of Pediatric Emergency, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
Specialty School of Paediatrics-Alma Mater Studiorum, Università di Bologna, 40138 Bologna, Italy.
Children (Basel). 2021 Jul 14;8(7):597. doi: 10.3390/children8070597.
Urinary tract infections (UTIs) are among the most common bacterial infections in children, and is the main pathogen responsible. Several guidelines, including the recently updated Italian guidelines, recommend amoxicillin-clavulanic acid (AMC) as a first-line antibiotic therapy in children with febrile UTIs. Given the current increasing rates of antibiotic resistance worldwide, this study aimed to investigate the three-year trend in the resistance rate of isolated from pediatric urine cultures (UCs) in a metropolitan area of northern Italy. We conducted a retrospective review of -positive, non-repetitive UCs collected in children aged from 1 month to 14 years, regardless of a diagnosis of UTI, catheter colonization, urine contamination, or asymptomatic bacteriuria. During the study period, the rate of resistance to AMC significantly increased from 17.6% to 40.2% ( < 0.001). Ciprofloxacin doubled its resistance rate from 9.1% to 16.3% ( = 0.007). The prevalence of multidrug-resistant rose from 3.9% to 9.2% ( = 0.015). The rate of resistance to other considered antibiotics remained stable, as did the prevalence of extended spectrum beta-lactamases and extensively resistant among isolates. These findings call into question the use of AMC as a first-line therapy for pediatric UTIs in our population, despite the indications of recent Italian guidelines.
尿路感染(UTIs)是儿童中最常见的细菌感染之一, 是主要病原体。包括最近更新的意大利指南在内的多项指南推荐阿莫西林-克拉维酸(AMC)作为发热性UTIs儿童的一线抗生素治疗。鉴于目前全球抗生素耐药率不断上升,本研究旨在调查意大利北部一个大都市地区从儿科尿培养(UCs)中分离出的 的耐药率三年趋势。我们对1个月至14岁儿童收集的阳性、非重复性UCs进行了回顾性审查,无论是否诊断为UTI、导管定植、尿液污染或无症状菌尿。在研究期间,对AMC的耐药率从17.6%显著增加到40.2%(<0.001)。环丙沙星的耐药率从9.1%翻倍至16.3%(=0.007)。多重耐药 的患病率从3.9%上升到9.2%(=0.015)。对其他考虑的抗生素的耐药率保持稳定,分离株中广谱β-内酰胺酶和广泛耐药 的患病率也保持稳定。尽管最近的意大利指南有相关指示,但这些发现对在我们人群中使用AMC作为儿科UTIs的一线治疗提出了质疑。